surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2013-0-1-2-60-66surgonco-160Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSПРИМЕНЕНИЕ ЭРИТРОПОЭТИНОВ В КОМБИНАЦИИ С ВНУТРИВЕННЫМИ ПРЕПАРАТАМИ ЖЕЛЕЗА ПРИ ХИМИОИНДУЦИРОВАННОЙ АНЕМИИ В ОНКОЛОГИИAPPLICATION OF ERITROPOETINS IN THE COMBINATION WITH INTRAVENOUS PREPARATIONS OF IRON AT CHEMIOINDUCED ANEMIA IN ONCOLOGYКудряшоваЛ. Н.KudryashovaL. N.

Кудряшова Любовь Николаевна - заведующий отделением паллиативной помощи РКОД, доцент кафедры  онкологии с курсами онкологии и патологической анатомии ИПО, кандидат медицинских наук.

450075, Республика Башкортостан, Уфа, Пр. Октября, д. 73/1, тел: 8 (347) 248-53-03,email: kudryashova-lyubov-777@mail.ru

Oncology Chair with  Courses of Oncology and Pathological Anatom, Ufa

kudryashova-lyubov-777@mail.ruБашкирский государственный медицинский университет; Республиканский клинический онкологический диспансерРоссияBashkir State Medical University; Republican Clinical Oncological DispanceryRussian Federation20133101201701-26066Copyright © Кудряшова Л.Н., 20172017Кудряшова Л.Н.Kudryashova L.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/160

Анемия,  являющаяся частым  осложнением химиотерапии в онкологии, значительно  снижает  качество  и  продолжительность жизни  больных  злокачественными опухолями. В статье  представлены международные рекомендации по применению эритропоэз-стимулирующих агентов при химиоиндуцированной анемии у онкологических больных. Даны понятия абсолютного и функционального дефицита железа. На основании анализа клинических исследований обосновано применение эритропоэтинов в комбинации с внутривенными препаратами железа.

The anemia  being  frequent complication of chemotherapy in oncology, considerably reduces quality and  life expectancy of patients with malignant tumors. The international recommendations  about  application of   eritropoez-stimulating agents  are   presented in article  at  chemioinduced anemia   at  oncological  patients. Concepts of  absolute and functional deficiency  of iron are given. On the  basis of the  analysis of clinical researches application eritropoetins in a combination with intravenous preparations of iron is proved. 

анемияэритропоэтинфункциональный дефицит железаабсолютный дефицит железаanemiaeritropoetinfunctional deficiency of ironabsolute deficiency of ironReferencesАбрамов М.Е. Анемия на фоне химиотерапии. Пути коррекции / М.Е. Абрамов // Фарматека. -№8. – 2012. – С. 50-54.Абрамов М.Е. Анемия на фоне химиотерапии. Пути коррекции / М.Е. Абрамов // Фарматека. -№8. – 2012. – С. 50-54.Моисеев С.В. Железо карбоксимальтозат – новый внутривенный препарат для лечения железодефицитной анемии / С.В. Моисеев / /Клиническая фармакология и терапия. – 2012. № 21(2). – С. 2-7.Моисеев С.В. Железо карбоксимальтозат – новый внутривенный препарат для лечения железодефицитной анемии / С.В. Моисеев / /Клиническая фармакология и терапия. – 2012. № 21(2). – С. 2-7.Новик А.В. Анемия и метаболические расстройства у онкологических больных / А.В. Новик // Практическая онкология. – 2009. Т.10. №3. – С. 131-139.Новик А.В. Анемия и метаболические расстройства у онкологических больных / А.В. Новик // Практическая онкология. – 2009. Т.10. №3. – С. 131-139.Павлов А.Д. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантным человеческим эритропоэтином / А.Д.Павлов, Е.Ф. Морщакова, А.Г. Румянцев // Современная онкология. 2002. №4. – С. 50–54.Павлов А.Д. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантным человеческим эритропоэтином / А.Д.Павлов, Е.Ф. Морщакова, А.Г. Румянцев // Современная онкология. 2002. №4. – С. 50–54.Птушкин В.В.Анемия в онкологии, подходы к лечению / В.В.Птушкин // Современная онкология. №1. – Т. 14. – 2012.– С. 14-18.Птушкин В.В.Анемия в онкологии, подходы к лечению / В.В.Птушкин // Современная онкология. №1. – Т. 14. – 2012.– С. 14-18.Aapro M., Osterborg A., Gasco P. et al. Prevalence and management of cancer related anaemia, iron deficiency and the specific role of i.v. iron // Ann. Oncol. – 2012. №10.Aapro M., Osterborg A., Gasco P. et al. Prevalence and management of cancer related anaemia, iron deficiency and the specific role of i.v. iron // Ann. Oncol. – 2012. №10.Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapyrelated anemia: a multicenter, open-label, randomized trial // J ClinOncol. – 2004. – Vol. 22. – P. 1301–1307.Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapyrelated anemia: a multicenter, open-label, randomized trial // J ClinOncol. – 2004. – Vol. 22. – P. 1301–1307.Auerbach M., Silberstein P., Webb R. et al. Darbepoietinalfa 500 mcg or 300 mcg once every three weeks with or without iron in patients with chemotherapy-induced anemia // Am J Hematol. – 2010. – Vol. 85(9). – P. 655–663.Auerbach M., Silberstein P., Webb R. et al. Darbepoietinalfa 500 mcg or 300 mcg once every three weeks with or without iron in patients with chemotherapy-induced anemia // Am J Hematol. – 2010. – Vol. 85(9). – P. 655–663.Auerbach M., Ballard H., Glaspy J. et al. Clinical update: intravenous iron for anaemia // Lancet. – 2007. – Vol. 369. – P. 1502-1504.Auerbach M., Ballard H., Glaspy J. et al. Clinical update: intravenous iron for anaemia // Lancet. – 2007. – Vol. 369. – P. 1502-1504.Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia // J ClinOncol. – 2008. – Vol. 26(10). – P. 1611–1618.Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia // J ClinOncol. – 2008. – Vol. 26(10). – P. 1611–1618.Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients // J. Natl.Cancer Inst. 2006. –Vol. 98. – P. 708–714.Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients // J. Natl.Cancer Inst. 2006. –Vol. 98. – P. 708–714.Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review // Cancer. – 2001. – Vol.91. – №12. – P. 2214 – 2221.Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review // Cancer. – 2001. – Vol.91. – №12. – P. 2214 – 2221.Crawford J., Cella D., Cleeland C.S. et al. Relationship between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy // Cancer. – 2002. – Vol. 95. – P. 888–895.Crawford J., Cella D., Cleeland C.S. et al. Relationship between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy // Cancer. – 2002. – Vol. 95. – P. 888–895.Dangsuwan P., Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy // Gynecol Oncol. – 2010. – Vol. 116(3). – P. 522–525.Dangsuwan P., Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy // Gynecol Oncol. – 2010. – Vol. 116(3). – P. 522–525.Demetri G.D., Kris M., Wade J. et al. Quality of life benefit in chemotherapy patients treated with epoetinalfa is independent of disease response or tumour type: results from a prospective community oncology study // J ClinOncol. – 1998. – Vol. 16. – P. 3412-3425.Demetri G.D., Kris M., Wade J. et al. Quality of life benefit in chemotherapy patients treated with epoetinalfa is independent of disease response or tumour type: results from a prospective community oncology study // J ClinOncol. – 1998. – Vol. 16. – P. 3412-3425.European Society for Medical Oncology ( ESMO). – Milan, 2010. С. 369– 374.European Society for Medical Oncology ( ESMO). – Milan, 2010. С. 369– 374.Gabrilove J.L., Cleeland C.S., Livingston R.B. et al. Clinical evaluation of once-weekly dosing of epoetinalfa in chemotherapy patients: improvement in haemoglobin and Quality of life are similar to threetimes-weekly dosing // J ClinOncol. – 2001. – Vol. 19. – P. 2875-2882.Gabrilove J.L., Cleeland C.S., Livingston R.B. et al. Clinical evaluation of once-weekly dosing of epoetinalfa in chemotherapy patients: improvement in haemoglobin and Quality of life are similar to threetimes-weekly dosing // J ClinOncol. – 2001. – Vol. 19. – P. 2875-2882.Glaspy J., Crawford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes // Br. J. Cancer. – 2010. – Vol. 102. – P. 1–315.Glaspy J., Crawford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes // Br. J. Cancer. – 2010. – Vol. 102. – P. 1–315.Glaspy J., Osterborg A., Ludwig H. et al. Evaluation of the association between (Hb) events and safety outcomes in cancer patients with chemotherapy induced anemia: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials of darbepoetin // Eur J Cancer Suppl. – 2007. – Vol. 5. P.Glaspy J., Osterborg A., Ludwig H. et al. Evaluation of the association between (Hb) events and safety outcomes in cancer patients with chemotherapy induced anemia: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials of darbepoetin // Eur J Cancer Suppl. – 2007. – Vol. 5. P.Groopman J, Itri L. Chemotherapy-induced anemia in adults: incidence and treatment // J Nat Cancer Inst. – 1999. – Vol. 91. – P. 1616–1634.Groopman J, Itri L. Chemotherapy-induced anemia in adults: incidence and treatment // J Nat Cancer Inst. – 1999. – Vol. 91. – P. 1616–1634.Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetinalfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. – Oncologist. – 2007. – Vol. 12. – Р. 231–242.Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetinalfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. – Oncologist. – 2007. – Vol. 12. – Р. 231–242.Khorana A., Francis C., Blumberg N. et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer // Arch Intern Med. – 2008. – Vol. 168. –P. 2377–2381.Khorana A., Francis C., Blumberg N. et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer // Arch Intern Med. – 2008. – Vol. 168. –P. 2377–2381.Littlewood T.J., Baretta E., Nortier J.W. et al. Effects of erythropoietin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomised, double-blind, placebo controlled trial // J Clin Oncol 2001. – Vol. 19. – P. 2865–2884.Littlewood T.J., Baretta E., Nortier J.W. et al. Effects of erythropoietin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomised, double-blind, placebo controlled trial // J Clin Oncol 2001. – Vol. 19. – P. 2865–2884.Ludwig H., Van Belle S., Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients // Eur J Cancer. 2004. №40. – Р. 2293–2306.Ludwig H., Van Belle S., Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients // Eur J Cancer. 2004. №40. – Р. 2293–2306.Ludwig H., Muldur E., Endler G. et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status // Haematologica. – 2011. –Vol. 96. – P.Ludwig H., Muldur E., Endler G. et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status // Haematologica. – 2011. –Vol. 96. – P.Moore R., Gaskell H., Rose P., Allan J. Metaanalysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord., 2011.Moore R., Gaskell H., Rose P., Allan J. Metaanalysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord., 2011.NCCN clinical practice guidelines. Cancer and chemotherapy-induced anemia. – 2010/ – Vol. 2: Available athttp://www.nccn.org/professionals/physician – gls/ PDF/anemia.pdf.NCCN clinical practice guidelines. Cancer and chemotherapy-induced anemia. – 2010/ – Vol. 2: Available athttp://www.nccn.org/professionals/physician – gls/ PDF/anemia.pdf.NCCN clinical practice guidelines. Cancer and chemotherapy-induced anemia. 2012. – Vol. 2. -Р.NCCN clinical practice guidelines. Cancer and chemotherapy-induced anemia. 2012. – Vol. 2. -Р.Stasi R., Abriani L., Beccaglia P. et al. Cancerrelated fatigue: evolving concepts in evaluation and treatment // Cancer. – 2003. – Vol. 98. – P. 1786–1801.Stasi R., Abriani L., Beccaglia P. et al. Cancerrelated fatigue: evolving concepts in evaluation and treatment // Cancer. – 2003. – Vol. 98. – P. 1786–1801.Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomized phase III trial of darbepoetinalfa in lung cancer patients receiving chemotherapy // J Natl Cancer Inst. – 2001. – Vol. 94. – P. 1211–1220.Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomized phase III trial of darbepoetinalfa in lung cancer patients receiving chemotherapy // J Natl Cancer Inst. – 2001. – Vol. 94. – P. 1211–1220.Williamson L.M., Lowe S., Love E.M. et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports // BMJ. – 1999. – Vol. 319. – P. 16–19.Williamson L.M., Lowe S., Love E.M. et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports // BMJ. – 1999. – Vol. 319. – P. 16–19.

The authors declare that there are no conflicts of interest present.